Welcome to the latest edition of our Healthcare & Life Sciences Market Update, in which we explore the evolving landscape of investment trends, regulatory challenges, and strategic opportunities shaping the global market....more
The response includes a considered implementation plan to strengthen the regulation of medical devices and in vitro diagnostics, improve patient safety, and foster innovation post-Brexit.
On 26 June 2022, the UK Medicines...more
7/1/2022
/ Consultation ,
Diagnostic Tests ,
Life Sciences ,
Medical Devices ,
Medicines and Healthcare Products Regulatory Agency (MHRA) ,
Pharmaceutical Industry ,
Proposed Regulation ,
Public Comment ,
Public Health ,
Technology ,
UK ,
UK Brexit
Welcome to the first edition of our European Healthcare & Life Sciences Market Update, a new report summarising key emerging trends, opportunities, and challenges facing the market in 2022. During the last 12 months, the...more
2/10/2022
/ Clinical Trials ,
Digital Health ,
EU ,
EU Clinical Trials Regulation (CTR) ,
Health Care Providers ,
Joint Venture ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Regulatory Agenda ,
Regulatory Standards ,
UK ,
Venture Capital
The agency’s consultation on the post-Brexit regulatory framework for medical devices and diagnostics aims to support innovation and sustainability, among other goals.
A 10-week consultation launched by the UK’s Medicines...more
The agreement provides guidance across several areas for the life sciences sector, though gaps remain.
The widely anticipated EU-UK Trade and Cooperation Agreement (the Agreement) came into effect on 1 January 2021 after...more
3/4/2021
/ Clinical Trials ,
Data Privacy ,
EU ,
Life Sciences ,
Manufacturers ,
Marketing Authorization Application ,
Medical Devices ,
Pharmaceutical Industry ,
Trade Agreements ,
UK ,
UK Brexit
The guidance provides helpful clarity on key regulatory changes impacting life sciences companies in the event of a no-deal Brexit.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published a...more
4/4/2019
/ Article 50 Treaty of the EU ,
EU ,
European Economic Area (EEA) ,
Health Care Providers ,
Healthcare ,
Life Sciences ,
Medicines and Healthcare Products Regulatory Agency (MHRA) ,
New Guidance ,
New Legislation ,
No-Deal Brexit ,
Pharmaceutical Industry ,
Time Extensions ,
UK ,
UK Brexit ,
Withdrawal Agreement